Department of Nutrition and Dietetics, Princess Alexandra Hospital, Brisbane, Australia; School of Medicine, University of Queensland, Brisbane, Australia; Translational Research Institute, Brisbane, Australia.
School of Medicine, University of Queensland, Brisbane, Australia; Translational Research Institute, Brisbane, Australia; Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia.
J Ren Nutr. 2015 Sep;25(5):399-403. doi: 10.1053/j.jrn.2015.01.017. Epub 2015 Mar 23.
There is increasing clinical evidence that patients with chronic kidney disease (CKD) have a distinctly dysbiotic intestinal bacterial community, termed the gut microbiota, which in turn drives a cascade of metabolic abnormalities, including uremic toxin production, inflammation, and immunosuppression, that ultimately promotes progressive kidney failure and cardiovascular disease. As the gut microbiota is intimately influenced by diet, the discovery of the kidney-gut axis has created new therapeutic opportunities for nutritional intervention. This review discusses the metabolic pathways linking dysbiotic gut microbiota with adverse health outcomes in patients with CKD, as well as novel therapeutic strategies for targeting these pathways involving dietary protein, fiber, prebiotics, probiotics, and synbiotics. These emerging nutritional interventions may ultimately lead to a paradigm shift in the conventional focus of dietary management in CKD.
越来越多的临床证据表明,慢性肾脏病(CKD)患者的肠道细菌群落存在明显的失调,这种失调的肠道细菌群落被称为肠道微生物群,它会引发一系列代谢异常,包括尿毒症毒素的产生、炎症和免疫抑制,最终导致进行性肾衰竭和心血管疾病。由于肠道微生物群受到饮食的密切影响,肾脏-肠道轴的发现为营养干预创造了新的治疗机会。本综述讨论了将肠道微生物群失调与 CKD 患者不良健康结果联系起来的代谢途径,以及针对这些途径的新型治疗策略,包括膳食蛋白质、纤维、益生元、益生菌和合生菌。这些新出现的营养干预措施最终可能导致 CKD 传统饮食管理重点的范式转变。